Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700527 · ClinicalTrials.gov registry record · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
A Phase 1 study of Radiation Toxicity and Toxicity, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT04700527: Recruiting Phase 1 study of Radiation Toxicity and Toxicity, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT04700527 is a Phase 1 study of Radiation Toxicity and Toxicity that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 122 participants, below the 463-participant average among 12 other Radiation Toxicity trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04700527, a Phase 1 study of Radiation Toxicity and Toxicity, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.
Primary Outcome
GI toxicities (PRO-CTCAE v5 for patients and CTCAE v5 for physicians) will be recorded and compared between the 2 groups to identify any differences.
Conditions Studied
Interventions
- DRUG Short Chain Fatty Acid
- DRUG Tapioca Flour
Study Locations (1)
North Carolina
- Flora Danquah - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2030-05 |
| Phase | Phase 1 |
What NCT04700527 shows while recruiting
NCT04700527 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 463-participant average among 12 other Radiation Toxicity trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Radiation Toxicity appearing as the primary indexed condition, and to 2 interventions - of which Short Chain Fatty Acid is the first listed.
NCT04700527 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04700527 about?
NCT04700527 is a clinical study titled "The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study". The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.
What is the current status of trial NCT04700527?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2023-12-15. Estimated completion is 2030-05.
What conditions does trial NCT04700527 study?
This clinical trial studies the following conditions: Radiation Toxicity, Toxicity.
What interventions are being tested in trial NCT04700527?
The interventions under investigation include: Short Chain Fatty Acid (DRUG), Tapioca Flour (DRUG).
Who is sponsoring clinical trial NCT04700527?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04700527 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Toxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04700527's enrollment target sits among peer trials
122 6th of 12 higher than 7 of 12 other Radiation Toxicity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Radiation Toxicity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
COMPLETED · Phase 1
-
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
COMPLETED · Phase 1
-
Monoclonal Antibody Therapy in Treating Patients With Leukemia
COMPLETED · Phase 1
-
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
RECRUITING · NA
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT05168163 · 122 participants · Phase 2
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI